MaxCyte(US:MXCT) Globenewswire·2025-11-05 13:05Core Insights - MaxCyte, Inc. announced preliminary results for Q3 2025, reporting total revenue of $6.8 million, a 16% decrease from $8.2 million in Q3 2024 [1][7] - The company reiterated its 2025 revenue guidance, expecting total cash, cash equivalents, and investments to be between $152 million and $155 million by year-end [10][15] Financial Performance - Core revenue for Q3 2025 was $6.4 million, down 21% from $8.1 million in Q3 2024 [6][7] - Revenue from Strategic Platform License (SPL) Program-related activities was $0.4 million, a significant increase of 1,663% compared to $24,000 in the same quarter of the previous year [6][7] - The gross margin for Q3 2025 was $5.2 million, representing a 77% gross margin, while the non-GAAP adjusted gross margin was 81% when excluding SPL Program-related revenue [7][21] Revenue Breakdown - Revenue sources for Q3 2025 included: - Instruments: $1.4 million (down 22%) - PAs and consumables: $2.6 million (down 25%) - Licenses: $1.8 million (down 29%) - Assay services: $248,000 (new revenue source) - Other: $402,000 (down 3%) [6][7] Client and Market Activity - The company added one new SPL client, Moonlight Bio, in October 2025, bringing the total number of SPL agreements to 32 [7] - The installed base of instruments increased to 830 units, up from 739 units in the previous year [9] Upcoming Events - Management will present at the Stifel Healthcare Conference on November 11, 2025, and the Stephens Investment Conference on November 19, 2025 [1][16]